0000000000866233

AUTHOR

David Arroyo

showing 4 related works from this author

Proteinuria-Lowering Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Chronic Kidney Disease Patients: A Real-World Multicentri…

2021

Control of dyslipidemia in chronic kidney disease (CKD) is not always guaranteed with statins and/or ezetimibe. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have opened up a new era in lipid control, but their effect on renal function and proteinuria in real life have not yet been evaluated. The aim of the present study was to analyze the evolution of renal function and proteinuria in a cohort of CKD patients treated with PCSK9i. This retrospective multicentric cohort study included CKD patients treated with PCSK9i. Baseline epidemiological data, comorbidities and laboratory findings (including estimated glomerular filtration rate [eGFR], proteinuria and lipid profile) …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismUrologyRenal functionurologic and male genital diseasesMicrobiologyBiochemistryArticleNephrotoxicitychemistry.chemical_compoundEzetimibePCSK9iCKDmedicinekidney functionMolecular BiologyCreatinineProteinuriamedicine.diagnostic_testbusiness.industrymedicine.diseaseQR1-502female genital diseases and pregnancy complicationschemistryInsuficiència renal crònicaproteinuriamedicine.symptomLipid profilebusinessDyslipidemiaKidney diseasemedicine.drugMetabolites
researchProduct

Additional file 1 of Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant …

2021

Additional file 1.

Data_FILES
researchProduct

An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients

2019

Background: Chronic kidney disease (CKD) is an independent risk factor for atherosclerotic disease. We hypothesized that CKD promotes a proatherogenic lipid profile modifying lipoprotein composition and particle number. Methods: Cross-sectional study in 395 non-diabetic individuals (209 CKD patients and 186 controls) without statin therapy. Conventional lipid determinations were combined with advanced lipoprotein profiling by nuclear magnetic resonance, and their discrimination ability was assessed by machine learning. Results: CKD patients showed an increase of very-low-density (VLDL) particles and a reduction of LDL particle size. Cholesterol and triglyceride content of VLDLs and intermed…

0301 basic medicineMaleVery low-density lipoproteinMagnetic Resonance SpectroscopyClinical BiochemistryMachine LearningPCSK9chemistry.chemical_compound0302 clinical medicineLp(a)Risk FactorsDrug DiscoveryProspective Studiesmedicine.diagnostic_testMiddle AgedLipids030220 oncology & carcinogenesisMolecular MedicineFemalelipids (amino acids peptides and proteins)Proprotein Convertase 9Adultmedicine.medical_specialtylipoprotein subfractionsLipoproteins03 medical and health sciencesInternal medicinemedicineHumansRisk factorRenal Insufficiency ChronicAgedPharmacologybusiness.industryCholesterolPCSK9dyslipidemiamedicine.diseaseAtherosclerosis030104 developmental biologyEndocrinologyCross-Sectional StudieschemistryCase-Control StudiesbusinessLipid profileDyslipidemiachronic kidney diseaseLipoproteinKidney disease
researchProduct

Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney dis…

2021

Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary renal disease. There is an increased rate of cardiovascular disease (CVD) in ADPKD. In this study, we evaluate the prevalence of cardiovascular risk factors, the achievement rates for treatment goals and cardiovascular events (CVE) in ADPKD and their relations with asymptomatic CVD in CKD from other etiologies (CKDoe) and controls. Methods: We evaluated 2445 CKD patients (2010–2012). The information collected was: clinical, anthropometric and analytical parameters, treatments and CVD evaluation (intima-media thickness (IMT), atheromatous plaque presence and ankle-brachial index (ABI)). Laborator…

MaleNephrologymedicine.medical_specialtyAutosomal dominant polycystic kidney diseaseRenal functionComorbiditylcsh:RC870-923urologic and male genital diseasesCarotid Intima-Media ThicknessAsymptomaticNephropathyAutosomal dominant polycystic kidney diseaseInternal medicineChronic kidney diseasemedicineHumansAnkle Brachial Indexcardiovascular diseasesRenal Insufficiency ChronicProteinuriabusiness.industryMiddle AgedPolycystic Kidney Autosomal DominantPrognosislcsh:Diseases of the genitourinary system. Urologymedicine.diseaseCardiovascular diseasePlaque Atheroscleroticfemale genital diseases and pregnancy complicationsNephropathyCor MalaltiesBlood pressureCardiovascular DiseasesHeart Disease Risk FactorsNephrologyDisease ProgressionInsuficiència renal crònicaFemalemedicine.symptombusinessResearch ArticleKidney disease
researchProduct